Advances in the treatment of fragile X syndrome.
Advances in the treatment of fragile X syndrome.
复制标题
DOI:
10.1542/peds.2008-0317
复制
发表时间:
2009-01
期刊:
影响因子:
8
通讯作者:
Tranfaglia M
中科院分区:
文献类型:
--
作者:
Hagerman RJ;Berry-Kravis E;Kaufmann WE;Ono MY;Tartaglia N;Lachiewicz A;Kronk R;Delahunty C;Hessl D;Visootsak J;Picker J;Gane L;Tranfaglia M
The FMR1 mutations can cause a variety of disabilities, including cognitive deficits, attention-deficit/hyperactivity disorder, autism, and other socioemotional problems, in individuals with the full mutation form (fragile X syndrome) and distinct difficulties, including primary ovarian insufficiency, neuropathy and the fragile X-associated tremor/ataxia syndrome, in some older premutation carriers. Therefore, multigenerational family involvement is commonly encountered when a proband is identified with a FMR1 mutation. Studies of metabotropic glutamate receptor 5 pathway antagonists in animal models of fragile X syndrome have demonstrated benefits in reducing seizures, improving behavior, and enhancing cognition. Trials of metabotropic glutamate receptor 5 antagonists are beginning with individuals with fragile X syndrome. Targeted treatments, medical and behavioral interventions, genetic counseling, and family supports are reviewed here.
登录
查看更多内容
影响因子:
2
作者:
Angkustsiri, Kathleen;Wirojanan, Juthamas;Hagerman, Randi J.
通讯作者:
Hagerman, Randi J.
DOI:
10.1089/cap.2006.16.525
发表时间:
2006-10-01
影响因子:
1.9
作者:
Berry-Kravis, Elizabeth;Krause, Sue Ellen;Hagerman, Randi
通讯作者:
Hagerman, Randi
影响因子:
5.3
作者:
Allen, EG;He, WY;Sherman, SL
通讯作者:
Sherman, SL
DOI:
10.1097/dbp.0b013e31817dc447
发表时间:
2008-08-01
影响因子:
2.4
作者:
Berry-Kravis, Elizabeth;Sumis, Allison;Greenough, William T.
通讯作者:
Greenough, William T.
影响因子:
2.9
作者:
Addae, Jonas I.;Ali, Nakisha;Stone, Trevor W.
通讯作者:
Stone, Trevor W.